ClinicalTrials.gg

Program

GDC-1261

A development code.

Its studies are mostly in Prostatic Neoplasms, led by Hoffmann-La Roche.

Furthest: phase 2, since Apr 13, 20261 company-led study, 1 open or runningNext primary completion: Nov 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche11 open or runningphase 2since Apr 13, 2026Apr 13, 2026Nov 30, 2027phase 2 · NCT07567846

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 13, 2026First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07567846 · 260 planned · United States, Australia, United Kingdom

Ahead

  1. Nov 30, 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT07567846

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07567846Prostatic Neoplasms · United States, Australia, United Kingdom2RecruitingNov 30, 2027260

How it is read

Names in the registry

  • “GDC-1261”, 1 entry

Codes read as this program: GDC1261.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.